Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Stock Nears Golden Cross, Signals Potential Upside With Strong Oncology Portfolio
Pfizer Inc (NYSE:PFE), one of the world's largest pharmaceutical firms, is on the verge of a bullish Golden Cross, a significant technical indicator suggesting potential upward momentum for the stock.
世界最大的藥品公司之一輝瑞公司（NYSE: PFE）即將迎來看好的金叉，這是一個重要的技術指標，表明該股票可能有向上的動力。
Currently, PFE stock is trading at around $30, showing a year-to-date gain of 2.6%, despite being down 16% over the past year.
目前，PFE股票交易價格約爲30美元，年初至今已上漲2.6％，儘管過去一年下跌了16％。
Chart created using Benzinga Pro
使用Benzinga Pro創建的圖表
The golden cross, where the short-term moving average crosses above the long-term moving average, is viewed by traders as a bullish signal.
金叉是指短期移動平均線上穿長期移動平均線，被交易員視爲積極信號。
Chart created using Benzinga Pro
使用Benzinga Pro創建的圖表
Pfizer's share price is above its 5, 20, and 50-day exponential moving averages, indicating a strong bullish trend. Specifically, PFE stock is trading above its 8-day simple moving average of $29.04, 20-day SMA of $28.35, and 50-day SMA of $28.37, all suggesting bullish pressure.
輝瑞的股價高於其5、20和50天的指數平均線，表明存在強烈的看好趨勢。具體而言，PFE股票的8天簡單移動平均線爲29.04美元，20天SMA爲28.35美元，50天SMA爲28.37美元，都說明有看多壓力。
Chart created using Benzinga Pro
使用Benzinga Pro創建的圖表
Additionally, Pfizer's Moving Average Convergence Divergence (MACD) indicator stands at 0.35, reinforcing the bullish outlook, although the Relative Strength Index (RSI) at 68.96 suggests the stock is nearing overbought territory.
此外，輝瑞的移動平均收斂散度（MACD）指標爲0.35，強化了看好的前景，儘管相對強度指數（RSI）爲68.96，說明股票即將進入超買區域。
Bollinger Bands further support the bullish sentiment, with the 25-period bands ranging from $26.73 to $29.45, with the stock trading over the upper bullish band.
布林帶進一步支持看多情緒，25週期的帶子從26.73美元到29.45美元，股票交易在上漲的上限帶子上。
Read Also: Pfizer And Roche Advance On Their Weight Loss Drug Journeys
閱讀更多：輝瑞和羅氏在減肥藥領域取得進展
Pfizer Catalysts – Comirnaty, Paxlovid, Seagen's Oncology Portfolio
輝瑞的催化劑--Comirnaty、Paxlovid、Seagen的腫瘤學組合
Looking ahead, Pfizer is anticipated to potentially exceed its financial guidance, driven by higher utilization of its products such as Comirnaty and Paxlovid, and strong performance from its newly acquired oncology portfolio from Seagen.
展望未來，輝瑞有望可能超越其財務指導，由於其產品，如Comirnaty和Paxlovid的高利用率，以及從Seagen收購的新獲得的腫瘤組合表現強勁。
Analysts forecast up to 30% growth in its oncology franchise and vaccine sales, contributing to Pfizer's ambitious goal of adding $25 billion in risk-adjusted revenue by 2030.
分析師預測其腫瘤治療領域和疫苗銷售增長高達30％，有助於輝瑞的宏偉目標，即到2030年增加250億美元的風險調整收入。
However, challenges remain. Demand for Pfizer's COVID-19 products and oncology drugs could fall short of expectations, and risks related to key product sales, pricing pressure, and pipeline developments persist.
然而，仍然存在挑戰。輝瑞COVID-19產品和腫瘤藥物的需求可能低於預期，且與主要產品銷售、價格壓力和管道開發相關的風險仍然存在。
Despite these concerns, the upcoming golden cross and recent bullish signals suggest Pfizer stock may be poised for further gains.
儘管存在這些擔憂，即將到來的金叉和最近的看多信號表明輝瑞股票可能會進一步上漲。
As Pfizer prepares to report its Q2 earnings, all eyes will be on whether these bullish indicators translate into sustained growth for the pharmaceutical giant.
隨着輝瑞準備報告其第二季度業績，所有人都將關注這些看多指標是否能夠轉化爲製藥巨頭持續增長。
- Pfizer, Cisco, Arch Capital And More: CNBC's 'Final Trades'
- 輝瑞，思科，艾奇資本和更多： CNBC的"最終交易"
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。